Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lanabecestat on Dabigatran PK in Healthy Subjects
NCT02568397Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lanabecestat in Alzheimer's disease (AD), sponsored by AstraZeneca. Primary endpoints: Maximum Concentration of Dabigatran and Area Under The Dabigatran Pharmacokinetic Concentration Versus Time Curve From Zero to Infinity. Started Oct 2015; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02568397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568397.